title: The development of immunoconjugates for targeted cancer therapy.
abstract: Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are beginning to show promise in the clinic. Immunoconjugates consist of three separate components: an antibody that binds to a cancer cell antigen with high specificity, an effector molecule that has a high capacity to kill the cancer cell, and a linker that will ensure the effector does not separate from the antibody during transit and will reliably release the effector to the cancer cell or tumour stroma. The high affinity antibody-antigen interaction allows specific and selective delivery of a range of effectors, including pharmacologic agents, radioisotopes, and toxins, to cancer cells. Some anticancer molecules are not well tolerated when administered systemically owing to unacceptable toxicity to the host. However, this limitation can be overcome through the linking of such cytotoxins to specific antibodies, which mask the toxic effects of the drug until it reaches its target. Conversely, many unconjugated antibodies are highly specific for a cancer target, but have low therapeutic potential and can be repurposed as delivery vehicles for highly potent effectors. In this Review, we summarize the successes and shortcomings of immunoconjugates, and discuss the future potential for the development of these therapies.
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA.
authors.forename: Brandon G
authors.initials: BG
authors.lastname: Smaglo
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA.
authors.forename: Dalal
authors.initials: D
authors.lastname: Aldeghaither
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA.
authors.forename: Louis M
authors.initials: LM
authors.lastname: Weiner
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D007116:Immunization, Passive / Q000379:methods* / Q000639:trends; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000639:trends*; D058990:Molecular Targeted Therapy / Q000639:trends; D009369:Neoplasms / Q000628:therapy*; D015202:Protein Engineering
chemical_list: D018796:Immunoconjugates